Hairy Cell Leukemia Clinical Trials

42 clinical trials for Hairy Cell Leukemia across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment — RECRUITING
• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia — RECRUITING · PHASE1
• Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant — RECRUITING · PHASE2
• Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant — RECRUITING · PHASE2
• Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant — RECRUITING · PHASE1
• Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia — RECRUITING · PHASE2
• A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) — RECRUITING · PHASE2
• Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. — RECRUITING · PHASE1
• Assessment of Disease Burden in Hairy Cell Leukemia — RECRUITING · NA
• Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management — RECRUITING
• Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management — RECRUITING
• Therapy Optimisation for the Treatment of Hairy Cell Leukemia — RECRUITING · PHASE2
• A PIVOTAL MULTICENTER TRIAL OF MOXETUMOMAB PASUDOTOX IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA — RECRUITING
• Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies — NOT_YET_RECRUITING
• Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies — NOT_YET_RECRUITING · PHASE1
• Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL — ACTIVE_NOT_RECRUITING · PHASE2
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies — COMPLETED · PHASE1
• Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia — COMPLETED · PHASE2
• A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia — COMPLETED · PHASE2
• Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) — TERMINATED
• Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy — COMPLETED
• Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab — COMPLETED · PHASE2
• Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. — TERMINATED
• LMB-2 to Treat Hairy Cell Leukemia — COMPLETED · PHASE2
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients — OTHER
• B-cell Chronic Lymphoid Malignancies Markers — OTHER
• Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer — WITHDRAWN · PHASE2
• Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. — TERMINATED · PHASE1
• A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia — COMPLETED · PHASE1
• Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer — COMPLETED
• Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease — COMPLETED
• Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study — COMPLETED
• Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia — TERMINATED · PHASE2
• A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia — COMPLETED · PHASE2
• Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease — OTHER · PHASE1

Refine this search